NasdaqGS - Nasdaq Real Time Price USD

Dyne Therapeutics, Inc. (DYN)

11.76

-0.58

(-4.70%)

At close: May 21 at 4:00:01 PM EDT

12.12

+0.36

+(3.06%)

After hours: May 21 at 7:39:00 PM EDT

Dyne Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights

- FDA (CDER) Type C meeting held in May 2025 for DYNE-101 in DM1 and Dyne plans to provide a regulatory update following receipt of meeting minutes - - Registrational Expansion Cohort of ACHIEVE Trial of DYNE-101 in DM1 initiated to support potential submission for U.S. Accelerated Approval in H1 2026 - - Registrational Expansion Cohort of DELIVER Trial of DYNE-251 in DMD fully enrolled to support potential submission for U.S. Accelerated Approval in early 2026 - WALTHAM, Mass., May 08, 2025 (GL

GlobeNewswire 13 days ago

DYN
-4.70%
EC grants orphan drug designation to Dyne Therapeutics’ DMD therapy

The company anticipates submitting a biologics licence application for accelerated approval in the US in early 2026.

Pharmaceutical Technology 26 days ago

DYN
-4.70%
Dyne Therapeutics Receives European Medicines Agency (EMA) Orphan Drug Designation for DYNE-251 in Duchenne Muscular Dystrophy

- Recently presented data demonstrated sustained functional improvement with DYNE-251 treatment through 18 months - - Data from the fully enrolled DELIVER registrational expansion cohort is planned for late 2025 - WALTHAM, Mass., April 24, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases, today announced that the European Commission (EC) has

GlobeNewswire 27 days ago

DYN
-4.70%
Why Sarepta Therapeutics And Other Genetics Stocks Just Got A Sizable Boost

Shares of gene therapy companies — including Sarepta Therapeutics — got a lift Monday after FDA's Marty Makary laid out his plans.

Investor's Business Daily 30 days ago

DYN
-4.70%

RNA

SRPT
Dyne Therapeutics Announces Chief Business Officer and Chief Scientific Officer Appointments

Vikram Ranade, PhD Vikram Ranade, PhD, Chief Business Officer (CBO) of Dyne Therapeutics Ranjan Batra, PhD Ranjan Batra, PhD, Chief Scientific Officer (CSO), of Dyne Therapeutics Oxana Beskrovnaya, PhD Oxana Beskrovnaya, PhD, Chief Innovation Officer (CIO), of Dyne Therapeutics - Vikram Ranade, PhD, appointed as chief business officer - - Ranjan Batra, PhD, appointed as chief scientific officer - - Oxana Beskrovnaya, PhD, transitioning to chief innovation officer - WALTHAM, Mass., April 15, 2025

GlobeNewswire last month

DYN
-4.70%
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WALTHAM, Mass., April 14, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases, today announced that it has granted inducement equity awards to three new employees. The awards were approved by Dyne’s Compensation Committee and made as an inducement material to the new employees’ acceptance of employment with Dyne in accordance with Nasdaq Listin

GlobeNewswire last month

DYN
-4.70%
Insider Purchases Worth US$1.06m See Losses As Dyne Therapeutics Market Value Drops To US$770m

Insiders who acquired US$1.06m worth of Dyne Therapeutics, Inc.'s ( NASDAQ:DYN ) stock at an average price of US$33.04...

Simply Wall St. last month

DYN
-4.70%
Biotech stocks slide as Marks resignation seen being negative for sector

Shares of several biotech and biopharma names are under pressure on Monday following the resignation of the head of the Food and Drug Administration’s Center for Biologics Evaluation and Research, Peter Marks. RBC Capital says the development is “not good for the biotech industry even beyond vaccines.” Voicing a similar opinion, BMO Capital told investors this morning that it sees the news as a “significant negative” for the biopharma and biotech sectors. “NOT GOOD” FOR BIOTECH SECTOR: RBC Capit

TipRanks last month

GLPG

GLPGF

PTCT
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Financial Officer

WALTHAM, Mass., March 20, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases, today announced it has granted inducement equity awards to its newly appointed Chief Financial Officer, Erick J. Lucera. The awards were approved by the Compensation Committee of Dyne and made as an inducement material to Mr. Lucera’s acceptance of employment with Dy

GlobeNewswire 2 months ago

DYN
-4.70%
Dyne Therapeutics Announces Appointment of Erick J. Lucera as Chief Financial Officer

Erick J. Lucera Erick J. Lucera, Chief Financial Officer (CFO) of Dyne Therapeutics - Proven financial leader brings decades of experience in capital allocation, business development and shareholder value creation - WALTHAM, Mass., March 20, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases, today announced the appointment of Erick J. Lucera,

GlobeNewswire 2 months ago

DYN
-4.70%
Dyne Therapeutics Announces New Long-Term Clinical Data from Phase 1/2 DELIVER Trial of DYNE-251 in Duchenne Muscular Dystrophy Demonstrating Unprecedented and Sustained Functional Improvement Through 18 Months

- Continued favorable safety profile for DYNE-251 - - DELIVER Registrational Expansion Cohort is fully enrolled; data from this cohort planned for late 2025 - - Potential for Biologics License Application submission for U.S. accelerated approval in early 2026 - WALTHAM, Mass., March 16, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases, today

GlobeNewswire 2 months ago

DYN
-4.70%
Dyne Therapeutics' $4.3 Billion Peak Sales Potential? Analyst Highlights Key Strengths And Risks

On Tuesday, BMO Capital Markets initiated coverage on Dyne Therapeutics, Inc. (NASDAQ:DYN), focused on developing therapies for genetically driven neuromuscular diseases. The company’s FORCE platform is designed to overcome limitations in delivery to muscle tissue and the central nervous system (CNS). Dyne has a broad pipeline for neuromuscular diseases, including clinical programs for myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD) and preclinical programs for facioscapulo

Benzinga 2 months ago

DYN
-4.70%
BMO Capital Initiates Coverage on Dyne Therapeutics With Outperform Rating

BMO Capital initiated coverage on Dyne Therapeutics with an Outperform rating and a $50 price target.

GuruFocus.com 2 months ago

DYN
-4.70%
Dyne Therapeutics to Present at Stifel 2025 Virtual CNS Forum

WALTHAM, Mass., March 11, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases, today announced that management is scheduled to participate in a fireside chat at the Stifel 2025 Virtual CNS Forum on Tuesday, March 18, 2025 at 4:00 p.m. ET. A live webcast will be available in the Investors & Media section of Dyne’s website at https://investors.dy

GlobeNewswire 2 months ago

DYN
-4.70%
Is Dyne Therapeutics (NASDAQ:DYN) In A Good Position To Deliver On Growth Plans?

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...

Simply Wall St. 2 months ago

DYN
-4.70%
Dyne Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

- Received FDA Fast Track Designation for DYNE-101 in DM1 - - Full enrollment of Registrational Expansion Cohort of ACHIEVE Trial of DYNE-101 in DM1 Planned for Mid-2025 to Support Submission for U.S. Accelerated Approval - - Full Enrollment of Registrational Expansion Cohort of DELIVER Trial of DYNE-251 in DMD Planned for Q1 2025 to Support Submission for U.S. Accelerated Approval - WALTHAM, Mass., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage neuromu

GlobeNewswire 2 months ago

DYN
-4.70%
Dyne Therapeutics Announces Upcoming Presentations at the 2025 MDA Clinical & Scientific Conference

- Data from DELIVER and ACHIEVE Clinicals Trial to be Presented - - Presentation on ACHIEVE Trial in DM1 and Company Symposium to Feature Data on the Use of Splicing Correction as a Prognostic Biomarker of Functional Outcomes in DM1 - - Presentations Add Insights into the FORCE™ Platform’s Ability to Deliver Targeted Therapeutics to Muscle and the CNS - WALTHAM, Mass., Feb. 14, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage neuromuscular disease company focused

GlobeNewswire 3 months ago

DYN
-4.70%
After Plunging -10.43% in 4 Weeks, Here's Why the Trend Might Reverse for Dyne Therapeutics (DYN)

Dyne Therapeutics (DYN) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Zacks 3 months ago

DYN
-4.70%
Dyne Therapeutics, Inc. (DYN): Among the Best Rebound Stocks to Invest In Now

We recently compiled a list of the 10 Best Rebound Stocks To Invest In Now. In this article, we are going to take a look at where Dyne Therapeutics, Inc. (NASDAQ:DYN) stands against the other rebound stocks. The United States economy is in a constant state of flux. In recent weeks, moderated growth, evolving monetary policies, […]

Insider Monkey 3 months ago

DYN
-4.70%
Dyne Therapeutics to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference

WALTHAM, Mass., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage neuromuscular disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that management is scheduled to present during a virtual fireside chat at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on Tuesday, February 11, 2025 at 4:00 p.m. ET. A live webcast will be available in the Investor

GlobeNewswire 3 months ago

DYN
-4.70%

Performance Overview

Return	DYN	S&P 500 (^GSPC)
YTD	-50.08%	-0.63%
1-Year	-63.96%	+9.83%
3-Year	+113.43%	+49.81%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Dyne Therapeutics, Inc. (DYN)

Dyne Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights

EC grants orphan drug designation to Dyne Therapeutics’ DMD therapy

Dyne Therapeutics Receives European Medicines Agency (EMA) Orphan Drug Designation for DYNE-251 in Duchenne Muscular Dystrophy

Why Sarepta Therapeutics And Other Genetics Stocks Just Got A Sizable Boost

Dyne Therapeutics Announces Chief Business Officer and Chief Scientific Officer Appointments

Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Insider Purchases Worth US$1.06m See Losses As Dyne Therapeutics Market Value Drops To US$770m

Biotech stocks slide as Marks resignation seen being negative for sector

Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Financial Officer

Dyne Therapeutics Announces Appointment of Erick J. Lucera as Chief Financial Officer

Dyne Therapeutics Announces New Long-Term Clinical Data from Phase 1/2 DELIVER Trial of DYNE-251 in Duchenne Muscular Dystrophy Demonstrating Unprecedented and Sustained Functional Improvement Through 18 Months

Dyne Therapeutics' $4.3 Billion Peak Sales Potential? Analyst Highlights Key Strengths And Risks

BMO Capital Initiates Coverage on Dyne Therapeutics With Outperform Rating

Dyne Therapeutics to Present at Stifel 2025 Virtual CNS Forum

Is Dyne Therapeutics (NASDAQ:DYN) In A Good Position To Deliver On Growth Plans?

Dyne Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

Dyne Therapeutics Announces Upcoming Presentations at the 2025 MDA Clinical & Scientific Conference

After Plunging -10.43% in 4 Weeks, Here's Why the Trend Might Reverse for Dyne Therapeutics (DYN)

Dyne Therapeutics, Inc. (DYN): Among the Best Rebound Stocks to Invest In Now

Dyne Therapeutics to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference

Performance Overview